Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML

NCT00669890 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

12

Enrollment

OTHER

Sponsor class

Stopped PI left institution

Conditions

Acute Myeloid Leukemia
Juvenile Myelomonocytic Leukemia
Myelodysplastic Syndrome

Interventions

DRUG: Gemtuzumab Ozogamicin
DRUG: Busulfan
DRUG: Cyclophosphamide
DRUG: Thymoglobulin
DRUG: Tacrolimus
DRUG: Mycophenolate Mofetil
DRUG: Methotrexate

Sponsor

New York Medical College